Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.56 |
| ▸ | PPARD | Q03181 | 4/20 | 0.56 |
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | TERT | O14746 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | F7 | P08709 | 2/20 | 0.56 |
| ▸ | F3 | P13726 | 2/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380888 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL258956 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL14798059 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL274867 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL15526298 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL648618 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL2014792 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL1603841 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL1654500 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL17744969 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 903 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118829251-A | Solar cell, preparation method thereof, photovoltaic module, system and power utilization device | 宁德时代新能源科技股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| WO-2024149820-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-07-18 | — | — | WO | claimed |
| CN-118255864-A | GIP receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118252921-A | Use of GIP receptor agonists | 杭州中美华东制药有限公司 | 2024-06-28 | — | — | CN | claimed |
| WO-2024133382-A1 | GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-118079021-A | Treatment or amelioration of metabolic disorders using GLP-1 receptor agonists coupled to Gastric Inhibitory Peptide Receptor (GIPR) antagonists | 美国安进公司 | 2024-05-28 | — | — | CN | claimed |
| US-11965039-B2 | Compstatin analogues and their medical uses | ZP SPV 3 K/S (DK) | 2024-04-23 | — | — | US | claimed |
| EP-4351630-A1 | TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | Antag Therapeutics ApS (DK) | 2024-04-17 | — | — | EP | claimed |
| EP-3551651-B1 | ACYLATED GLP-1/GLP-2 DUAL AGONISTS | ZEALAND PHARMA AS (DK) | 2024-03-06 | — | — | EP | claimed |
| CN-117384274-A | Acylated GLP-1/GLP-2 dual agonists | 西兰制药公司 | 2024-01-12 | — | — | CN | claimed |
| EP-3046573-A2 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2016-07-27 | — | — | EP | claimed |
| WO-2015067716-A1 | GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2015-05-14 | — | — | WO | claimed |
| WO-2015040182-A2 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2015-03-26 | — | — | WO | claimed |
| CN-103906528-A | Methods of treating diabetes with sustained release formulations of GLP-1 receptor agonists | AMYLIN PHARMACEUTICALS INC | 2014-07-02 | — | — | CN | claimed |
| US-7541430-B2 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | claimed |
| US-20070244054-A1 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2007-10-18 | — | — | US | claimed |
| EP-1625158-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | claimed |
| WO-2004099246-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| US-4440781-A | TRANQUILIZERS; ANTICONVULSANTS; ANTIDEPRESSANTS; ALCOHOL AND TOBACCO WITHDRAWAL | THE VINOXEN COMPANY, INC. (US) | 1984-04-03 | — | — | US | claimed |
| US-4097665-A | Diacylnucleosides and process for preparing the same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-06-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11965039-B2 | Compstatin analogues and their medical uses | C1QBP, C9, VIP | LMNA 1380/4885TSHR 1041/4885NFKB1 2017/4885 |
| US-20070244054-A1 | Peptides for use in treating obesity | NPY4R, GLP1R, NPY1R | LMNA 3088/4885TSHR 296/4885NFKB1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.